Stockreport

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Artelo Biosciences, Inc.  (ARTL) 
US:NASDAQ Investor Relations: artelobio.com/investors
PDF ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions  ART27.13 Interim P [Read more]